The Post-COVID-19 Complications in Children: Hemolytic Uremic Syndrome, New-Onset Vasculitis, and Acute Hepatitis

authors:

avatar Vahid Ziaee ORCID 1 , 2 , 3 , avatar Raheleh Assari ORCID 1 , 2 , *

Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran
Children’s Medical Center, Pediatrics Center of Excellence, Tehran, Iran
Pediatric Rheumatology Research Group, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
Iranian Journal of Pediatrics: Vol.32, issue 4; e128727
published online: July 20, 2022
article type: Editorial
received: June 1, 2022
accepted: June 14, 2022
DOI: https://doi.org/10.5812/ijp-128727

how to cite: Ziaee V, Assari R . The Post-COVID-19 Complications in Children: Hemolytic Uremic Syndrome, New-Onset Vasculitis, and Acute Hepatitis. Iran J Pediatr. 2022;32(4):e128727. https://doi.org/10.5812/ijp-128727.

References

  • 1.

    Centers for Disease Control and Prevention Health Alert Network. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). Maryland, USA: Center for Preparedness and Response; 2020, [cited May22]. Available from: https://emergency.cdc.gov/han/2020/han00432.asp.

  • 2.

    Dionne A, Son MBF, Randolph AG. An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2. Pediatr Infect Dis J. 2022;41(1):e6-9. [PubMed ID: 34889873]. [PubMed Central ID: PMC8658063]. https://doi.org/10.1097/INF.0000000000003393.

  • 3.

    Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771-8. [PubMed ID: 32410760]. [PubMed Central ID: PMC7220177]. https://doi.org/10.1016/s0140-6736(20)31103-x.

  • 4.

    Belhadjer Z, Meot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. Circulation. 2020;142(5):429-36. [PubMed ID: 32418446]. https://doi.org/10.1161/CIRCULATIONAHA.120.048360.

  • 5.

    Balgradean M, Cinteza E, Aria LA, Matei RL, Marin L, Moga L, et al. Clinical and Pathogenic Correlations Between SARS-CoV-2 Infection and Hemolytic Uremic Syndrome in Children. Maedica (Bucur). 2020;15(3):376-80. [PubMed ID: 33312255]. [PubMed Central ID: PMC7726516]. https://doi.org/10.26574/maedica.2020.15.3.376.

  • 6.

    Trimarchi H, Coppo R. COVID-19 and acute kidney injury in pediatric subjects: is there a place for eculizumab treatment? J Nephrol. 2020;33(6):1119-20. [PubMed ID: 32996110]. [PubMed Central ID: PMC7523686]. https://doi.org/10.1007/s40620-020-00859-1.

  • 7.

    Gill J, Hebert CA, Colbert GB. COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy. J Nephrol. 2022;35(1):317-21. [PubMed ID: 34427905]. [PubMed Central ID: PMC8383924]. https://doi.org/10.1007/s40620-021-01125-8.

  • 8.

    Kronbichler A, Geetha D, Smith RM, Egan AC, Bajema IM, Schonermarck U, et al. The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum. Autoimmun Rev. 2021;20(12):102986. [PubMed ID: 34718165]. [PubMed Central ID: PMC8552556]. https://doi.org/10.1016/j.autrev.2021.102986.

  • 9.

    Raeeskarami SR, Mousavi SH, Ashouri M, Akbariasbagh P, Assari R, Naderi S. Could COVID-19 Trigger Presentation or Exacerbation of Vasculitides? (A 14-Year-Old Girl with Newly Diagnosed GPA After COVID-19 Infection). Iran J Pediatr. 2021;31(3). e110597. https://doi.org/10.5812/ijp.110597.

  • 10.

    Fireizen Y, Shahriary C, Imperial ME, Randhawa I, Nianiaris N, Ovunc B. Pediatric P-ANCA vasculitis following COVID-19. Pediatr Pulmonol. 2021;56(10):3422-4. [PubMed ID: 34379888]. [PubMed Central ID: PMC8441809]. https://doi.org/10.1002/ppul.25612.

  • 11.

    Cantor A, Miller J, Zachariah P, DaSilva B, Margolis K, Martinez M. Acute Hepatitis Is a Prominent Presentation of the Multisystem Inflammatory Syndrome in Children: A Single-Center Report. Hepatology. 2020;72(5):1522-7. [PubMed ID: 32810894]. [PubMed Central ID: PMC7655704]. https://doi.org/10.1002/hep.31526.

  • 12.

    Perez A, Cantor A, Rudolph B, Miller J, Kogan-Liberman D, Gao Q, et al. Liver involvement in children with SARS-COV-2 infection: Two distinct clinical phenotypes caused by the same virus. Liver Int. 2021;41(9):2068-75. [PubMed ID: 33826804]. [PubMed Central ID: PMC8251417]. https://doi.org/10.1111/liv.14887.

  • 13.

    Samarasekera U. Mystery outbreak of severe acute hepatitis in children. Lancet Gastroenterol Hepatol. 2022;7(7):601. https://doi.org/10.1016/s2468-1253(22)00159-5.

  • 14.

    Cevik M, Rasmussen AL, Bogoch ,I, Kindrachuk J. Acute hepatitis of unknown origin in children. BMJ. 2022;377:o1197. [PubMed ID: 35580879]. https://doi.org/10.1136/bmj.o1197.

  • 15.

    Rohani P, Sohouli MH, Ezoddin N, Alimadadi H. Evaluation of Acute Severe Hepatitis of Unknown Origin in Three Children in Iran: A case series. Iran J Pediatr. 2022;32(3). e128010. https://doi.org/10.5812/ijp-128010.

  • 16.

    Sacco K, Castagnoli R, Vakkilainen S, Liu C, Delmonte OM, Oguz C, et al. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. Nat Med. 2022;28(5):1050-62. [PubMed ID: 35177862]. [PubMed Central ID: PMC9119950]. https://doi.org/10.1038/s41591-022-01724-3.

  • 17.

    Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183(4):968-981 e7. [PubMed ID: 32966765]. [PubMed Central ID: PMC7474869]. https://doi.org/10.1016/j.cell.2020.09.016.

  • 18.

    Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol. 2005;141(3):381-7. [PubMed ID: 16045726]. [PubMed Central ID: PMC1809464]. https://doi.org/10.1111/j.1365-2249.2005.02821.x.

  • 19.

    Hur G, Song MS, Sohn S, Lee HD, Kim GB, Cho HJ, et al. Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea. Korean Circ J. 2019;49(2):183-91. [PubMed ID: 30468032]. [PubMed Central ID: PMC6351283]. https://doi.org/10.4070/kcj.2018.0214.